Latest news with #oncology
Yahoo
3 hours ago
- Business
- Yahoo
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues to experience oncology cost trend below expectations coming into 2025. Evolent is reiterating its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and its full year Adjusted EBITDA guidance of $135M-165M. John Johnson, Evolent's Chief Financial Officer, noted, "We are pleased to see oncology trend remaining below forecast now for the first two thirds of the quarter. We remain confident in meeting or beating the expectations we set for the 2nd quarter and full year. If these trends continue through June, we would anticipate being in the top half of our range for Q2 Adjusted EBITDA." The company also announced it signed a Commitment Letter with Ares Management Credit funds, securing the option to borrow additional non-dilutive capital, if needed, to address its 2025 Convertible Notes while leaving incremental working capital on its balance sheet to support Evolent's accelerating organic growth pipeline. Seth Blackley, Evolent's Chief Executive Officer, noted, "A recent acceleration in our business development activities has led us to significantly increase our forecast for new revenue bookings going into 2026. This option for incremental, non-dilutive capital availability ensures we can execute on any working capital needs associated with that higher growth forecast." About Evolent Evolent (NYSE: EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting Contacts:investorrelations@ Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to the company's full year and second quarter 2025 guidance, availability of borrowings under the commitment letter, sufficiency of capital for the company's working capital needs associated with a higher growth forecast, and the company's forecast for new revenue bookings going into 2026. The company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. By their nature, forward-looking statements are subject to numerous factors, risks and uncertainties that could cause actual outcomes and results to be materially different from those projected. These risks and uncertainties are discussed under the headings "Forward-Looking Statements - Cautionary Language," and "Risk Factors," in the company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the U.S. Securities and Exchange Commission (the "SEC"), and in the company's other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. Except for any ongoing obligation to disclose material information as required by the United States federal securities laws, the company does not have any intention or obligation to publicly update or revise any forward-looking statements after issuing this release, whether to reflect any future events or circumstances or otherwise Non-GAAP Measures The company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include loss on repayment/extinguishment of debt; gain (loss) from equity method investees, loss on option exercise, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), gain (loss) on disposal of non-strategic assets, right-of-use asset impairments, losses on lease terminations, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant. View original content to download multimedia: SOURCE Evolent Health, Inc.
Yahoo
17 hours ago
- Business
- Yahoo
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QIAGEN N.V. QGEN has announced a new partnership with South Korea-based GENCURIX, Inc. to develop oncology assays for use on the QIAcuityDx digital PCR (dPCR) platform. The molecular diagnostics company is the first development partner under QIAGEN's QIAcuityDx Partnering Program, designed to enable the generation of a broad menu of in-vitro diagnostics (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics. The latest development is expected to significantly boost the company's Precision Diagnostics business under the Diagnostic Solutions product group. Shares of QIAGEN stayed flat in the aftermarket following the announcement of the news yesterday. The collaboration with GENCURIX represents the first step in building a robust and innovative assay ecosystem for the QIAcuityDx platform, backed by QIAGEN's distribution capabilities and technical support. Accordingly, market sentiment surrounding QGEN stock should stay positive, driven by the news. QIAGEN has a market capitalization of $10.35 billion. The company has an earnings yield of 5%, well above the industry's -29.3% yield. In the trailing four quarters, it delivered an average earnings surprise of 4.9%. The QIAcuityDx Partnering Program aims to support third-party assay development on QIAcuityDx. A member of the QIAcuity family of dPCR systems, the platform had more than 2,700 cumulative placements since its launch by the end of 2024. These menu initiatives for clinical applications will leverage this installed base and build on the 2024 milestone of launching more than 130 new assays for QIAcuity for research applications, complemented by the extensive menu of custom assays available on QIAGEN's GeneGlobe platform. Image Source: Zacks Investment Research Under this first partnership, GENCURIX will apply its proven expertise in complex, multiplex IVD assay development to create oncology tests. GENCURIX will begin developing multiple oncology assays and pursue IVD regulatory approvals. As the legal manufacturer of the assays, GENCURIX will be fully responsible for obtaining and maintaining all necessary regulatory approvals and certifications. Upon approval, the assays will be marketed through QIAGEN's global commercial infrastructure as part of the QIAcuityDx Partnering Program, ensuring streamlined access for laboratories worldwide. Per a research report, the global IVD market was valued at $108.30 billion in 2024 and is expected to grow at a compound annual rate of 5.6% through 2030. The growing demand for accurate, rapid and personalized diagnostic solutions globally is fueling the market's growth. The expansion is also supported by the integration of digital health, AI and data analytics into diagnostic platforms, helping enhance test accuracy and clinical decision-making. Last week, the company announced a new global collaboration with Incyte to develop a novel diagnostic panel to support the latter's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Under the agreement terms, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. Over the past year, QGEN shares have risen 8.1% against the industry's 16.1% decline. QIAGEN currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Cencora COR. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Cencora each carry a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 5.2% to $2.04 in the past 30 days. Shares of the company have rallied 35.1% in the past year compared with the industry's 7.7% growth. Its earnings yield of 8.5% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.8% in the past year. Estimates for the company's 2025 earnings per share have jumped 2.8% to 73 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Cencora's fiscal 2025 earnings per share have increased 0.4% to $15.75 in the past 30 days. Shares of the company have jumped 25.9% in the past year against the industry's 16.2% fall. COR's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6%. In the last reported quarter, it delivered an earnings surprise of 8.3%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
a day ago
- Business
- Globe and Mail
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on multiple modalities, including small molecules, antibody-drug conjugates (ADCs) and immuno-oncology biologics. The addition of Seagen in 2023 also strengthened its position in oncology by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and in the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer's oncology revenues grew 7% on an operational basis in the first quarter of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage development, like sasanlimab, vepdegestrant and sigvotatug vedotin. In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter's dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline. Pfizer is also working on expanding the labels of approved oncology products like Padcev and Adcetris, among others. With all the above developments, Pfizer's future in cancer treatment looks promising. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 6.8% so far this year against an increase of 0.2% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.77 forward earnings, lower than 15.05 for the industry and the stock's 5-year mean of 10.90. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
Yahoo
a day ago
- Business
- Yahoo
Cardiff Oncology to share CRDF-004 trial data on July 29
The company said last night, 'In addition to today's medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.' The data is from Cardiff 's lead program in first-line RAS-mutated metastatic colorectal cancer. Shares of Cardiff Oncology (CRDF) are down 8%, or 30c, to $3.10 in premarket trading. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CRDF: Disclaimer & DisclosureReport an Issue Confident Buy Rating for Cardiff Oncology Amid Strategic Developments and Promising Trial Prospects Cardiff Oncology Appoints New Chief Medical Officer Cardiff Oncology appoints Roger Sidhu as chief medical officer Cardiff Oncology's Onvansertib: Anticipated Phase II Results and Market Potential Drive Buy Rating Cardiff Oncology 'highly encouraged' by onvansertib data presented at ASCO
Yahoo
a day ago
- Business
- Yahoo
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group ( today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101, NCT06375044) at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of SIM0500 in patients with relapsed/refractory multiple myeloma (RRMM). SIM0500 (formerly SCR-8572) is a humanized trispecific antibody targeting GPRC5D, BCMA and CD3, developed using Simcere Zaiming's proprietary T-cell engager polyspecific antibody platform. [1] "In the last few years, BCMA and GPRC5D-targeted therapies have demonstrated significant promise in treating RRMM and have been anticipated as the cornerstones of the next chapter in the pursuit of curing myeloma. SIM0500 is the natural evolution of combining these targets with the aim to optimize outcomes in the RRMM," said Dr. Joshua Richter, M.D., Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, Director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai, and Principal Investigator. "SIM0500 is designed to bind to two tumor antigens, GPRC5D and BCMA. It has shown strong T-cell cytotoxicity against multiple myeloma cells in preclinical studies," said Prof. Shaji Kumar, M.D. "I look forward to participating in the Phase 1 study of SIM0500 to evaluate the safety and efficacy of this potentially transformative therapy in patients with RRMM." "We are quite pleased with the safety and encouraging efficacy results generated to-date in the ongoing dose escalation and look forward to the extension of the SIM0500 Phase 1 trial to the US. This marks an important step forward in Simcere Zaiming's continued commitment to advance new oncology treatments and elevate the standard of care for patients with RRMM," said Yongyu Wang, M.D., Chief Medical Officer, Simcere Zaiming. SIM0500 is being developed in partnership with AbbVie. About SIM0500 SIM0500 stands as a potentially best-in-class candidate, poised to offer novel therapeutic options for solving drug resistance encountered in existing multiple myeloma treatments. In April 2024, the FDA awarded SIM0500 a Fast Track designation. In January 2025, Simcere Zaiming entered into an agreement with AbbVie granting AbbVie an option to license SIM0500. SIM0500 is an investigational agent that has not been approved by the FDA or any other regulatory authority. About SIM0500-101 Phase 1 study SIM0500 is currently being investigated in a phase 1 clinical trial both in US and in China. Preliminary data suggested a good safety profile, desired pharmacokinetic profile of SIM0500 with encouraging efficacy. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including COSELA®, Enweida®, Endostar®, and Enlituo®. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. This press release contains forward-looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause such differences include, but are not limited to, the inherent uncertainties in clinical development, regulatory approval processes, competitive developments, and other risks detailed in our filings with the Hong Kong Stock Exchange. [1]. FU Y, You S, Wei M, et al.: A novel T cell engager targeting BCMA and GPRC5D showed promising preclinical activity with low toxic risk for multiple myeloma treatment. Cancer Res (2024) 83 (7_Supplement): 1883 Contacts:Simcere ZaimingPR contacts: pr@ contacts: ir@ View original content: SOURCE Simcere Zaiming Sign in to access your portfolio
